Rybelsus (Oral Semaglutide) in Children Under 12: What the Off-Label Evidence Actually Shows

FDA Approval Status and the Under-12 Gap

Rybelsus received FDA approval in September 2019 for glycemic control in adults with type 2 diabetes. The approved label specifies adult use only. No pediatric indication has been granted for any age group, and no New Drug Application supplement targeting children under 18 for oral semaglutide has been accepted as of the 2025 review date.

The FDA Pediatric Research Equity Act (PREA) requires manufacturers to study drugs in pediatric populations when the drug treats a disease that also occurs in children. Novo Nordisk has not submitted a completed pediatric study plan for oral semaglutide in children under 12 to date, making any such prescribing unambiguously off-label. [1]

What "Off-Label" Means Clinically

Off-label prescribing is legal for licensed physicians and is common in pediatrics. The American Academy of Pediatrics estimates that more than 70% of drugs administered to hospitalized children are used off-label or are unlicensed. [2] That precedent does not make off-label use appropriate for every agent. The absence of pediatric pharmacokinetic data for oral semaglutide in children under 12 means dosing guidance is extrapolated from adult data, which may not translate reliably.

Why the Under-12 Group Is Distinct

Children under 12 are not simply smaller adults. Gastric emptying rates, intestinal absorptive surface area, and hepatic enzyme maturation all differ from adult physiology, affecting oral drug bioavailability. Oral semaglutide's absorption depends critically on co-administration with the absorption enhancer sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC). The interplay between SNAC-mediated absorption and pediatric gastric physiology has not been characterized in any published study. [3]

Why Youth-Onset Type 2 Diabetes Makes This Question Urgent

Youth-onset type 2 diabetes is not rare or mild. The TODAY (Treatment Options for type 2 Diabetes in Adolescents and Youth) trial (N=699, ages 10-17) found that glycemic control deteriorated faster in youth than in adult-onset disease, with a 52% rate of treatment failure on metformin at 3.86 years of follow-up. [4] Beta-cell function declined at roughly twice the rate seen in adult-onset type 2 diabetes. [4]

The Metformin Ceiling

Metformin remains the ADA-recommended first-line oral agent for youth ages 10 and older, but TODAY demonstrated its limitations clearly. When metformin monotherapy failed, adding rosiglitazone (no longer available) or lifestyle intervention improved outcomes modestly. No GLP-1 receptor agonist was part of the original TODAY protocol. The 2024 ADA Standards of Care (Section 14) now explicitly recommend liraglutide injection for youth age 12 and older with type 2 diabetes inadequately controlled on metformin, and insulin remains a cornerstone agent at any age. [5]

Obesity in Children Under 12

Childhood obesity affects roughly 14.7 million U.S. Children and adolescents, per CDC data covering 2017-2020. [6] In the 6-to-11-year age band, obesity prevalence reached 20.3%. [6] The surge in severe obesity in this group has intensified interest in pharmacotherapy. The American Academy of Pediatrics' 2023 Clinical Practice Guideline for the Evaluation and Treatment of Children with Obesity recommends offering pharmacotherapy as an adjunct to intensive health behavior and lifestyle treatment for children age 12 and older. [7] That guideline does not extend pharmacotherapy recommendations to children under 12 except in the context of clinical trials or specialist evaluation.

Pharmacokinetics of Oral Semaglutide: Adult Data and Pediatric Unknowns

In adults, oral semaglutide 14 mg achieves a mean peak plasma concentration (Cmax) of approximately 12 nmol/L with high intra-individual variability (coefficient of variation roughly 89%). [8] Absolute bioavailability averages only about 1%, compared to approximately 89% for subcutaneous semaglutide. [8] That narrow and variable absorption window means small physiologic differences can produce clinically meaningful changes in drug exposure.

SNAC Dependency and Gastric pH

SNAC raises local gastric pH transiently, protecting semaglutide from proteolytic degradation long enough for absorption across the gastric epithelium. [3] Pediatric gastric acid secretion per kilogram of body weight is higher relative to adults in some age bands, and basal gastric pH fluctuates more in younger children. These factors could reduce SNAC efficacy, though no published data confirm this in children under 12. [9]

Weight-Based Dosing Challenges

Adult Rybelsus dosing starts at 3 mg once daily for 30 days, escalates to 7 mg, and reaches a maximum of 14 mg. There is no weight-adjusted dosing table. A 25 kg child receiving the lowest adult tablet dose (3 mg) would receive 0.12 mg/kg, compared to the 0.05 mg/kg exposure in an average 60 kg adult. The clinical significance of this relative dose difference is unknown because pediatric GLP-1 receptor sensitivity data for oral semaglutide do not exist in the published literature. [10]

Injectable vs. Oral Semaglutide in Pediatric Populations: What the Trials Show

The only pediatric semaglutide trial with publicly reported results used the subcutaneous formulation (Ozempic/Wegovy), not oral Rybelsus. The STEP TEENS trial (NCT04102189, N=201, ages 12-17) demonstrated that weekly subcutaneous semaglutide 2.4 mg produced a mean BMI reduction of 16.1% from baseline over 68 weeks, versus a 0.6% increase in the placebo group (P<0.001). [11] The New England Journal of Medicine published these results in 2022. [11]

SCALE Kids and the Age 10 Floor

A separate pediatric trial, NCT05063656 (SCALE Kids), studied subcutaneous semaglutide 2.4 mg in children ages 6 to 11 with obesity. Results from this trial were presented at the European Congress on Obesity in May 2024 and showed a mean BMI reduction of approximately 7.7% versus 1.6% for placebo at 68 weeks. This is the youngest age group for which semaglutide efficacy data now exist, but the drug studied was the injectable formulation, not oral semaglutide. [12]

The Oral Formulation Gap

No published randomized controlled trial has assessed oral semaglutide specifically in children under 12. Searching ClinicalTrials.gov for "semaglutide" combined with "oral" and "pediatric" or "children" returns no completed or ongoing interventional trials targeting children under 12 as of July 2025. [13] Extrapolating STEP TEENS or SCALE Kids results to oral Rybelsus in this age group involves two layers of uncertainty: the oral vs. Injectable formulation difference and the age-group difference.

Safety Signals Relevant to the Pediatric Population

GLP-1 receptor agonists share a class-level adverse effect profile. In adults, nausea affects roughly 20% of patients initiating semaglutide, vomiting affects 10-12%, and diarrhea affects 9%. [14] In children, these gastrointestinal effects carry additional risks: dehydration in active younger children, aversion to eating that could impair linear growth, and difficulty adhering to the fasting requirement (Rybelsus must be taken 30-60 minutes before food with no more than 4 oz of plain water).

Thyroid C-Cell Concerns

Semaglutide carries an FDA black-box warning for thyroid C-cell tumors based on rodent carcinogenicity studies. The relevance to humans remains uncertain, but the FDA label states that semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). [15] Pediatric endocrinologists should screen for these conditions before any consideration of off-label use.

Growth and Development

No data assess the impact of oral semaglutide on linear growth, bone density, or pubertal progression in children under 12. This is not a trivial gap. GLP-1 receptors are expressed in bone, and animal studies have shown effects on bone formation. [16] Lean mass loss accompanying GLP-1-mediated weight reduction is also documented in adult trials, raising questions about implications during critical developmental windows.

Pancreatitis Risk

Acute pancreatitis has been reported in GLP-1 receptor agonist trials. In SUSTAIN-6 (N=3,297 adults), pancreatitis occurred in 0.7% of semaglutide-treated patients versus 0.5% in placebo. [17] Pediatric pancreatitis carries distinct causes and outcomes compared to adult pancreatitis. No pediatric-specific pancreatitis data for oral semaglutide exist. [17]

Current Guideline Recommendations for Pediatric Weight and Diabetes Management

ADA 2024 Standards of Care

The ADA's 2024 Standards of Care in Diabetes (Section 14, "Children and Adolescents") state: "For youth with type 2 diabetes, metformin and insulin are the recommended pharmacologic agents." [5] The document adds liraglutide as an option for youth age 12 and older based on the ELLIPSE trial, but does not mention oral semaglutide for any pediatric age group. [5]

AAP 2023 Obesity Guideline

The American Academy of Pediatrics' Clinical Practice Guideline on obesity treatment (Pediatrics, 2023) recommends intensive health behavior and lifestyle treatment as the foundation for all ages, with pharmacotherapy added for children age 12 and older when clinically indicated. [7] The guideline explicitly notes that evidence is insufficient to recommend pharmacotherapy for children under 12 outside of clinical trial settings. [7]

Endocrine Society Guidance

The Endocrine Society's Clinical Practice Guideline on obesity pharmacotherapy does not include specific recommendations for oral semaglutide in children under 12. The society recommends individualized assessment by a pediatric endocrinologist when considering off-label agents. [18]

When Might a Specialist Consider Off-Label Oral Semaglutide in a Child Under 12?

This is the zone where published evidence ends and clinical judgment begins. A pediatric endocrinologist might discuss off-label oral semaglutide in a child under 12 only after exhausting approved options, in the context of severe comorbidity, and under conditions that mirror clinical trial rigor. The scenario is rare. There is no peer-reviewed case series reporting outcomes for oral semaglutide specifically in children under 12 as of this article's review date.

A reasonable specialist framework for this situation includes the following sequential considerations:

1. Confirm failure of or contraindication to all age-appropriate approved therapies, including metformin (age 10 and older for type 2 diabetes), lifestyle intervention, and referral for bariatric evaluation if BMI thresholds are met.
2. Document a multidisciplinary team discussion including a pediatric endocrinologist, dietitian, and behavioral health specialist.
3. Obtain informed consent from parents or guardians that explicitly covers the absence of safety and efficacy data for this formulation in this age group.
4. Start at the lowest available dose (3 mg) and extend each dose escalation period beyond the 30-day adult schedule to allow slower titration.
5. Monitor weight, height velocity, pubertal staging, fasting glucose, HbA1c, lipase, thyroid function, and gastrointestinal symptoms at every visit, with the first follow-up no later than 4 weeks after initiation.
6. Enroll the patient in a registry or case report if possible to contribute to the evidence base.

This framework does not constitute a clinical recommendation. It reflects the minimum standard of care a specialist would likely apply if proceeding off-label.

What Families and Referring Physicians Should Know

Primary care physicians and families asking about Rybelsus for a child under 12 should understand a few concrete points.

Rybelsus is not approved for any person under 18. Any prescription in a child is off-label and should originate from a pediatric endocrinologist, not a general practitioner or weight-loss clinic. [1]

The fasting requirement alone is a practical barrier. Rybelsus must be taken upon waking, with only 4 oz of plain water, and no food, drink, or other medications for at least 30 minutes, preferably 60 minutes. Adherence to this protocol in young children is difficult to achieve consistently. [8]

Injectable semaglutide has a larger, though still limited, evidence base in pediatric patients than oral semaglutide. If a GLP-1 receptor agonist is being seriously considered for a child under 12, subcutaneous semaglutide's data from SCALE Kids are marginally more informative than the complete absence of oral-formulation data. [12]

Access and insurance coverage for off-label use in this population will almost universally require prior authorization with substantial documentation. Most payers deny GLP-1 agents for children under the FDA-approved minimum ages without extensive appeals.

Ongoing Research and the Near-Term Evidence Horizon

The injectable semaglutide SCALE Kids results (NCT05063656) have shifted the conversation. Novo Nordisk presented the 6-to-11-year subcutaneous semaglutide data at scientific meetings in 2024, but as of July 2025 peer-reviewed publication in a major journal has not been confirmed. [12] An FDA indication for subcutaneous semaglutide in younger children may follow if the full data package is submitted and reviewed favorably.

Whether an oral semaglutide pediatric trial will follow is speculative. The development pathway for oral formulations in young children is complicated by tablet-swallowing ability, SNAC-related gastric physiology concerns, and the difficulty of conducting bioequivalence studies in very young populations. [3]

Liraglutide injection (Saxenda) carries an FDA approval for chronic weight management in children age 12 and older, backed by the SCALE Teens trial (N=251, 56-week weight change of -4.5% vs. +0.5% placebo, P<0.001). [19] This approval established a precedent that GLP-1 receptor agonist obesity indications can extend to pediatric populations when data support it, but the age floor has not moved below 12 for any approved agent.

The TODAY2 follow-up study (NCT01775072) tracked participants from the original TODAY trial into young adulthood, documenting severe long-term complications including nephropathy, retinopathy, and cardiovascular events at alarming rates in the third decade of life. [20] These outcomes underscore the urgency of better pediatric treatment options and make the off-label prescribing question clinically relevant even when the evidence is thin.